Zobrazeno 1 - 10
of 169
pro vyhledávání: '"Warfarin/adverse effects"'
Publikováno v:
Revista Portuguesa de Nefrologia e Hipertensão, Vol 37, Iss 2, Pp 106-111 (2023)
Wunderlich syndrome is a rare condition characterized by atraumatic spontaneous renal hemorrhage that can have serious associated complications, especially in chronic kidney disease and end-stage kidney disease patients due to their complexity. Diag
Externí odkaz:
https://doaj.org/article/b61f264fca514820ae59f378dc7a16c7
Autor:
Petra Bistrovic, Anica Sabljic, Ivona Kovacevic, Tomislav Cikara, Tatjana Keres, Tomo Lucijanic, Josko Mitrovic, Diana Delic-Brkljacic, Sime Manola, Marko Lucijanic
Introduction: There are conflicting data on prior oral-anticoagulant (OAC) use and outcomes of hospitalized COVID-19 patients. Due to uncertainties regarding associated risks with the prior OAC use, we have investigated this issue in a large cohort o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b438a24431e8fa1d030b453774d4df6
https://doi.org/10.1016/j.ijcard.2022.11.051
https://doi.org/10.1016/j.ijcard.2022.11.051
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Mar, Philip L., Gopinathannair, Rakesh, Gengler, Brooke E., Chung, Mina K., Perez, Arturo, Dukes, Jonathan, Ezekowitz, Michael D., Lakkireddy, Dhanunjaya, Lip, Gregory Y. H., Miletello, Mike, Noseworthy, Peter A., Reiffel, James, Tisdale, James E., Olshansky, Brian
Publikováno v:
Mar, P L, Gopinathannair, R, Gengler, B E, Chung, M K, Perez, A, Dukes, J, Ezekowitz, M D, Lakkireddy, D, Lip, G Y H, Miletello, M, Noseworthy, P A, Reiffel, J, Tisdale, J E, Olshansky, B & from the American Heart Association Electrocardiography & Arrhythmias Committee of the Council of Clinical Cardiology 2022, ' Drug Interactions Affecting Oral Anticoagulant Use ', Circulation. Arrhythmia and Electrophysiology, vol. 15, no. 6, e007956 . https://doi.org/10.1161/CIRCEP.121.007956
Circ Arrhythm Electrophysiol
Circ Arrhythm Electrophysiol
Oral anticoagulants (OACs) are medications commonly used in patients with atrial fibrillation and other cardiovascular conditions. Both warfarin and direct oral anticoagulants are susceptible to drug-drug interactions (DDIs). DDIs are an important ca
Publikováno v:
Einstein (São Paulo), Vol 10, Iss 1, Pp 110-115 (2012)
Oral anticoagulants are among the drugs with the greatest numberof drug interactions. The concomitant use of several medications isa common practice in patients with cardiovascular problems, whooften also present with depression; therefore, the proba
Externí odkaz:
https://doaj.org/article/66579e14feb842dd91c1e3fb0cb047b2
Autor:
Kathrine Parker, John Hartemink, Ananya Saha, Roshni Mitra, Penny Lewis, Albert Power, Satarupa Choudhuri, Sandip Mitra, Jecko Thachil
Publikováno v:
Parker, K, Hartemink, J, Saha, A, Mitra, R, Lewis, P, Power, A, Choudhuri, S, Mitra, S & Thachil, J 2022, ' A systematic review of the efficacy and safety of anticoagulants in advanced chronic kidney disease ', Journal of Nephrology . https://doi.org/10.1007/s40620-022-01413-x
Parker, K, Hartemink, J, Saha, A, Mitra, R, Lewis, P, Power, A, Choudhuri, S, Mitra, S & Thachil, J 2022, ' A systematic review of the efficacy and safety of anticoagulants in advanced chronic kidney disease ', Journal of Nephrology, vol. 35, no. 8, pp. 2015-2033 . https://doi.org/10.1007/s40620-022-01413-x
Parker, K, Hartemink, J, Saha, A, Mitra, R, Lewis, P, Power, A, Choudhuri, S, Mitra, S & Thachil, J 2022, ' A systematic review of the efficacy and safety of anticoagulants in advanced chronic kidney disease ', Journal of Nephrology, vol. 35, no. 8, pp. 2015-2033 . https://doi.org/10.1007/s40620-022-01413-x
BackgroundPatients with chronic kidney disease (CKD) have an increased risk of venous thromboembolism (VTE) and atrial fibrillation (AF). Anticoagulants have not been studied in randomised controlled trials with CrCl MethodsWe conducted a systematic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::904cfee5ca9e03a8e242c35bdc9dc982
http://www.scopus.com/inward/record.url?scp=85137019706&partnerID=8YFLogxK
http://www.scopus.com/inward/record.url?scp=85137019706&partnerID=8YFLogxK
Autor:
Stefan Agewall, Jesper K. Jensen, Thomas G. von Lueder, Ingrid Hopper, Dipak Kotecha, Dan Atar, Moo Hyun Kim, Victor L. Serebruany, Robert J. Mentz
Publikováno v:
von Lueder, T G, Atar, D, Agewall, S, Jensen, J K, Hopper, I, Kotecha, D, Mentz, R J, Kim, M H & Serebruany, V L 2019, ' All-Cause Mortality and Cardiovascular Outcomes With Non-Vitamin K Oral Anticoagulants Versus Warfarin in Patients With Heart Failure in the Food and Drug Administration Adverse Event Reporting System ', American Journal of Therapeutics, vol. 26, no. 6, pp. e671-e678 . https://doi.org/10.1097/MJT.0000000000000883
BACKGROUND: Many patients with heart failure (HF) are treated with warfarin or non-vitamin K oral anticoagulants (NOACs). Randomized outcome-driven comparisons of different anticoagulant strategies in HF are lacking. Data from international, governme
Publikováno v:
Medicina Interna, Volume: 26, Issue: 1, Pages: 52-59, Published: MAR 2019
A nefropatia associada aos anticoagulantes orais (NAAO), da qual o paradigma é a nefropatia associada à varfarina, tem sido definida de modo variável na literatura, dificultando avaliações epidemiológicas e clínicas rigorosas. A maior parte do
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1126318a4d3023fb5fab417b2bbed5f
Autor:
Gregory Y.H. Lip
Publikováno v:
Lip, G Y H 2019, ' The safety of NOACs in atrial fibrillation patient subgroups : A narrative review ', International Journal of Clinical Practice, vol. 73, no. 2, e13285 . https://doi.org/10.1111/ijcp.13285
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
AIM: Four non-vitamin K oral anticoagulants (NOACs) have been evaluated in clinical trials for the prevention of stroke in patients with atrial fibrillation (AF). Although each of the NOACs have been shown to be at least non-inferior to warfarin for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c31a03596faff0bfee86879256cde1c4
https://vbn.aau.dk/ws/files/293589076/The_safety_of_NOACs_in_atrial_fibrillation_patient_subgroups_A_narrative_review.pdf
https://vbn.aau.dk/ws/files/293589076/The_safety_of_NOACs_in_atrial_fibrillation_patient_subgroups_A_narrative_review.pdf
Autor:
Al-Jehani, Mariann1 (AUTHOR), Al-Husayni, Faisal2,3 (AUTHOR), Almaqati, Ahmed3 (AUTHOR), Shahbaz, Jomanah1 (AUTHOR), Albugami, Saad1,2,4 (AUTHOR), Alameen, Wail4 (AUTHOR)
Publikováno v:
Case Reports in Cardiology. 8/31/2021, p1-5. 5p.